Results 91 to 100 of about 22,470,337 (287)

ICOS‐ImmunoPET Monitors T Cell Activation After Combination Immune Checkpoint Blockade in a Mouse Model of Melanoma Brain Metastasis

Advanced Science, EarlyView.
ICOS‐immunoPET noninvasively visualizes activated T cells in melanoma brain metastases following combined anti‐PD‐1/anti‐CTLA‐4 therapy. Clinical translation of this imaging approach may improve patient stratification and treatment monitoring and serve as a quantitative imaging endpoint to support immunotherapy development and clinical trials in brain ...
Renesmee C. Kuo, Rohit Verma, Sydney C. Nagy, Mausam Kalita, Samuel Aubert, Josué Ballesteros‐Álvarez, Pedro Machado Almeida, Hannes Vogel, Israt S. Alam, Michael Lim, Michelle L. James   +10 more
wiley   +1 more source

Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma

Haematologica, 2008
Background The tumor microenvironment is important for the behavior of cancer. We assessed the distribution and biological significance of FOXP3+ regulatory T-cells (Treg) in lymphomas.Design and Methods The absolute number of intratumoral FOXP3+ cells ...
Alexandar Tzankov, Cecile Meier, Petra Hirschmann, Philip Went, Stefano A. Pileri, Stephan Dirnhofer   +5 more
doaj   +1 more source

EBV‐Driven ODC1 Upregulation Enhances Polyamine Anabolism to Promote Viral Replication and Cisplatin Resistance in Nasopharyngeal Carcinoma

Advanced Science, EarlyView.
EBV‑BZLF1 initiates ODC1‑driven polyamine anabolism that correlates with poor clinical prognosis in nasopharyngeal carcinoma. The ODC1–spermidine axis promotes viral replication, cell proliferation and innate immune evasion. Pharmacological inhibition of ODC1 rescues cisplatin sensitivity, establishing ODC1 as a viable therapeutic target for EBV ...
Yueshuo Li, Xudong Hu, Chenxing Yang, Na Liu, Lin Wang, Xi Cai, Min Tang, Ya Cao, Li Shang, Feng Shi   +9 more
wiley   +1 more source

Treatment of Diffuse Large B-Cell Lymphoma

Journal of Clinical and Experimental Hematopathology, 2016
Diffuse large B-cell lymphoma (DLBCL) comprises a heterogeneous group with pathophysiological, genetic and clinical features. Many patients can be cured with R-CHOP therapy, which is the current standard regimen. Despite recent progress in improving patient survival, the 40% survival of DLBCL patients remains poor.
openaire   +3 more sources

SynNotch Receptors for Visualizing Immunoreceptor Force Transmission and Downstream Signaling In Vivo

Advanced Science, EarlyView.
A mechanically activated SynNotch reporter platform enables detection of force transmission through receptors as they mediate immune cell interactions. Targeting CD40 on B cells and TCR on T cells records force‐induced reporter activation across 2D coculture, 3D organoid, and implanted in mice, which also reveal force‐amplification of immune receptor ...
Menglan Li, Jintian Lyu, Kaitao Li, Ameya Dravid, Deepali Balasubramani, Amir H. K. Ashkezari, Hyun‐Kyu Choi, Gabriel A. Kwong, Ankur Singh, Cheng Zhu   +9 more
wiley   +1 more source

The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies

Advanced Science, EarlyView.
This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang, Zhicheng Zhou, Xue Jiang, Zhenguang Du, Yangyang Zhan, Xinli Liu   +5 more
wiley   +1 more source

A Case of a Rapidly Progressive Small Bowel Lymphoma with High Ki-67 Expression

The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2017
Primary intestinal lymphoma is a rare disease. It accounts for approximately 1∼4% of gastrointestinal malignancy. Extranodal lymphoma of the intestine mainly arises from B cells.
Jiyeon Yoo, Hee Jun Kang, Hyungkeun Kim, Sujeong Han, Seung Hyun Oh, Sung Hoon Jung, Jung Hwan Oh, Eun Jung Jeon   +7 more
doaj   +1 more source

Treatment of Diffuse Large B Cell Lymphoma

The Korean Journal of Internal Medicine, 2012
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in all countries and all age groups. DLBCL is potentially curable, and the outcome of patients with DLBCL has completely changed with the introduction of therapy involving the monoclonal antibody rituximab in combination with chemotherapy.
openaire   +2 more sources

CAR‐Engineered Cell Therapies Beyond Cancer: Reprogramming Fibrosis and Immune‐Mediated Inflammation

Advanced Science, EarlyView.
CAR‐engineered cell therapies are expanding beyond cancer toward immune resetting, pathological‐cell clearance, matrix remodeling, and microenvironmental reprogramming in autoimmune, inflammatory, and fibrotic diseases. This Review compares CAR‐T, CAR‐macrophage, and CAR‐NK platforms and proposes controllable spatiotemporal reprogramming to align ...
Peng Jun Xu, Zhou Jing Zhang, Jing Jin, Hai Yuan Xu, Ya Xin Gu, Qian Qian Yang, You Lang Zhou   +6 more
wiley   +1 more source

Diffuse large B-cell lymphoma of the small intestine in a patient with refractory coeliac disease. [PDF]

, 2019
INTRODUCTION: Coeliac disease enteropathy is associated with an increased risk of lymphomas. Enteropathy-associated T-cell lymphoma is the principal malignancy related to coeliac disease.
Raja Ali, Raja Affendi, Mohamed Rose, Isa, Ahmad Affandi, Khairunisa, Masir, Noraidah, Abd Shukor, Nordashima   +4 more
core   +1 more source